Bryostatin-1 for latent virus reactivation in HIV-infected patients on antiretroviral therapy

AIDS
Carolina GutiérrezSantiago Moreno

Abstract

The protein kinase C (PKC) agonist bryostatin-1 has shown significant ex-vivo potency to revert HIV-1 latency, compared with other latency reversing agents (LRA). The safety of this candidate LRA remains to be proven in treated HIV-1-infected patients. In this pilot, double-blind phase I clinical-trial (NCT 02269605), we included aviraemic HIV-1-infected patients on triple antiretroviral therapy to evaluate the effects of two different single doses of bryostatin-1 (10 or 20 μg/m) compared with placebo. Twelve patients were included, four in each arm. Bryostatin-1 was well tolerated in all participants. Two patients in the 20 μg/m arm developed grade 1 headache and myalgia. No detectable increases of cell-associated unspliced (CA-US) HIV-1-RNA were observed in any study arm, nor differences in HIV-1 mRNA dynamics between arms (P = 0.44). The frequency of samples with low-level viraemia did not differ between arms and low-level viraemia did not correlate with CA-US HIV-1-RNA levels (P = 0.676). No changes were detected on protein kinase C (PKC) activity and in biomarkers of inflammation (sCD14 and interleukin-6) in any study arm. After the single dose of bryostatin-1, plasma concentrations were under detection limits in all the p...Continue Reading

References

Dec 16, 1997·Proceedings of the National Academy of Sciences of the United States of America·T W ChunA S Fauci
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M L VarterasianA M Al-Katib
Jan 31, 2002·Annual Review of Medicine·Joel N BlanksonRobert F Siliciano
Oct 29, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M L AmadorM Hidalgo
Dec 6, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Basil F El-RayesPhilip A Philip
Jul 20, 2010·Current HIV Research·Moisés PérezEduardo Muñoz
Sep 25, 2012·Immunity·Evelyn Eisele, Robert F Siliciano
Dec 29, 2012·Drug Discovery Today·Sifei Xing, Robert F Siliciano
Mar 13, 2014·The Journal of Infectious Diseases·Nancy M ArchinDavid M Margolis
Mar 31, 2015·The Journal of Clinical Investigation·Gregory M LairdRobert F Siliciano
Jul 23, 2015·Scientific Reports·Laura DíazMa Ángeles Muñoz-Fernández
Sep 18, 2015·PLoS Pathogens·Ole S SøgaardMartin Tolstrup
Oct 3, 2015·Antiviral Research·Marta Martínez-BonetMaria Ángeles Muñoz-Fernández
Nov 14, 2015·Scientific Reports·Marta Martínez-BonetMaria Ángeles Muñoz-Fernández

❮ Previous
Next ❯

Citations

Oct 21, 2016·Open Forum Infectious Diseases·Héloïse M DelagrèverieJonathan Z Li
Dec 21, 2016·The Journal of Immunology : Official Journal of the American Association of Immunologists·Clélia DentalMichel J Tremblay
May 24, 2018·Future Medicinal Chemistry·Xiang Rong TianKirk R Gustafson
Sep 14, 2019·International Journal of Molecular Sciences·Maria G DesimioMargherita Doria
Aug 20, 2019·Current Topics in Medicinal Chemistry·Kenji MaedaHiroaki Takeuchi
Aug 15, 2018·Antimicrobial Agents and Chemotherapy·Adam M SpivakVicente Planelles
Apr 22, 2020·Nature Communications·Clayton HardmanPaul A Wender
Sep 9, 2016·Current Opinion in HIV and AIDS·Thomas A RasmussenSharon R Lewin
Aug 31, 2017·BMC Infectious Diseases·Kristian ThorlundD William Cameron
May 11, 2018·Reviews in Medical Virology·Marcial GarcíaNorma Rallón
Nov 9, 2018·Frontiers in Immunology·Jorge CarrilloJulià Blanco
Dec 20, 2018·The Journal of General Virology·Uddhav TimilsinaRitu Gaur
Apr 4, 2019·Retrovirology·Gerlinde VansantZeger Debyser
Sep 10, 2019·Frontiers in Microbiology·Paul W DentonMartin Tolstrup
Nov 5, 2019·Frontiers in Immunology·Amanda B MacedoAlberto Bosque
Jan 8, 2020·Viruses·Jan KristoffRobbie B Mailliard
Jul 1, 2020·Frontiers in Immunology·Janne Tegder MartinsenOle Schmeltz Søgaard
May 7, 2020·Proceedings of the National Academy of Sciences of the United States of America·Jack L SloanePaul A Wender
May 19, 2017·The Journal of Infectious Diseases·David M Margolis, Nancie M Archin
Feb 17, 2018·PLoS Computational Biology·Vipul Gupta, Narendra M Dixit
Nov 4, 2017·Annual Review of Medicine·Adam M Spivak, Vicente Planelles
Jan 29, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Renée M Van der SluisSharon R Lewin
Jul 2, 2020·The Journal of Clinical Investigation·Caroline DufourNicolas Chomont
Sep 10, 2020·Frontiers in Cellular and Infection Microbiology·Wenli MuScott G Kitchen
Apr 13, 2017·Current HIV/AIDS Reports·Radwa R Sharaf, Jonathan Z Li
Jul 18, 2017·The Journal of Clinical Investigation·Nancie M ArchinDavid M Margolis

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
ELISA

Clinical Trials Mentioned

NCT02269605

Related Concepts

Related Feeds

Cancer Imaging

Imaging techniques, including CT and MR, have become essential to tumor detection, diagnosis, and monitoring. Here is the latest research on cancer imaging.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

HIV/AIDS-Related Malignancies

HIV/AIDS infection increases the risk of non-communicable diseases common in the aged including HIV/AIDS-related malignancies. Discover the latest research in HIV/AIDS-related malignancies.